This is a prospective, open-label, multi-center, single arm study designed to assess continued safety and effectiveness of the HeartLight System during commercial use in participants being treated for drug refractory, symptomatic, paroxysmal atrial fibrillation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years or older
planned for catheter ablation due to symptomatic paroxysmal atrial fibrillation
failure of at least one anti-arrhythmic drug
others
You may not be if
overall good health as established by multiple criteria
